Reset
Showing 2 of 2 academic articles

Phase 2a/b randomised placebo-controlled dose-escalation trial of triheptanoin for ataxia-telangiectasia: treating mitochondrial dysfunction with anaplerosisResearch in context

Matthew Lynch, Sophie Manoy, Peter D. Sly, Claire E. Wainwright et al. • EBioMedicine (2025)

Summary: Background: Ataxia-telangiectasia (A-T) is a rare multisystem disease characterised by neurodegenerative cerebellar ataxia, lung disease, immune deficiency, high cancer risk, and mitochondrial dysfunction. A-T cells demonstrate de...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.ebiom.2025.105840

The voice of depression: speech features as biomarkers for major depressive disorder

Felix Menne, Felix Dörr, Julia Schräder, Johannes Tröger et al. • BMC Psychiatry (2024)

Abstract Background Psychiatry faces a challenge due to the lack of objective biomarkers, as current assessments are based on subjective evaluations. Automated speech analysis shows promise in detecting symptom severity in depressed patient...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12888-024-06253-6